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Asthma and allergic rhinitis (AR) are 
diseases characterized by the presence of chronic 
inflammation and oxidative stress. Concomitant 
nasal and bronchial inflammation in atopic asthma 
and AR (1-2) lead to the hypothesis of the so-called 
united airway disease (UAD) in patients with allergic 
airway disease (3). On the basis of this concept, it is 
important to detect and to monitor the presence of 
inflammation and oxidative stress in the upper and 
lower airways in patients with UAD both in the 
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United airway disease (UAD) concept proposed that asthma and rhinitis are both different clinical 
manifestation of a single inflammatory process. The aim of this study is to assess in upper and lower 
airways the level of inflammation and oxidative stress and to investigate the relationship between 
biomarkers in persistent allergic rhinitis (PER) and in concomitant asthma with PER. By a cross-
sectional study we measured oral and nasal (FE
NO
)
 
and oral and nasal EBC 8-isoprostane, LTB
4
 and 
PGE
2 
in children with PER (n=14) and with PER and concomitant intermittent asthma (IA; n=25), mild 
persistent asthma (mA; n=28), moderate persistent asthma (MA; n=13)  and in Healthy Controls (HCs; 
n=13). Oral and nasal FE
NO
 concentrations were increased in children with PER, IA, mA and MA when 
compared with HCs. Nasal 8-isoprostane was higher in EBC of children with PER and asthma than in 
HCs. Oral and nasal LTB
4
 were higher in EBC of children with PER and mA than in HCs. Oral and 
nasal PGE
2
 concentrations were higher in EBC of children with PER than in HCs. Positive correlations 
between oral and nasal biomarkers were found in IA for LTB4 and PGE2, in mA for FE
NO
, 8-isoprostane, 
LTB
4 
and PGE
2
, and in MA for PGE
2
. No correlations were observed in children with PER and HCs. Our 
results suggest that non-invasive markers of inflammation and oxidative stress might be useful to study 
the relationships between oral and nasal compartments in allergic children with PER and concomitant 
asthma with the aim of defining the UAD.
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and the concentrations of 8-isoprostane, LTB
4
 and 
PGE
2
 in oral and nasal EBC of pediatric patients 
since the use of non-invasive techniques are simple 
and easy to apply in children with atopic airway 
disease.
MATERIALS AND METHODS
Study design
The cross-sectional study included allergic children 
monosensitized to house dust mites with PER with or 
without concomitant asthma. All of them were evaluated 
by performing skin prick test (SPT), spirometry, oral and 
nasal FE
NO
, oral and nasal EBC collection and symptom 
score evaluation. Patients were studied in a stable ambient 
condition to avoid the influence on the reliability of the 
above-mentioned procedures by temperature, barometric 
pressure and humidity. The study was approved by the 
local Ethics Committee, and written informed consent 
was obtained from the parents of the patients enrolled in 
the study.
Subjects
Sixty-six children with PER and with concomitant 
controlled asthma (31 males and 35 females), 14 children 
with PER without asthma (8 males and 6 females), and 
13 age-matched healthy controls (7 males and 6 females) 
(HCs), which had negative SPT, were consecutively 
enrolled. Children were recruited among outpatients 
attending the Pulmonology/Allergy Department of the 
Italian National Research Council in Palermo. The study 
subjects had no acute respiratory symptoms during the 
previous four weeks.
Assessment of PER and asthma were based on current 
ARIA and GINA guidelines, respectively (14-15). PER 
diagnosis was performed at the study entry according to 
the history of nasal symptoms and positive SPT. Among 
the asthmatics, 25 children had intermittent asthma 
(IA) (treated with short-acting β
2
-agonists on demand 
during the previous 3 months), 28 had mild persistent 
asthma (mA) (treated with 100 μg of fluticasone bid 
during the previous two months), and 13 children had 
moderate persistent asthma (MA) (treated with 250 μg of 
fluticasone propionate plus salmeterol 50 μg bid during 
the previous two months). All asthmatic children had AR 
and concluded the treatment for rhinitis (antihistamines 
or topical steroid treatment) 2 months before entering the 
study.
No patients had acute or chronic respiratory infections 
or exacerbation of asthma in the previous month or 
anatomical nasal disorders (i.e. nasal polyposis). Within 
one day from the EBC collection, all subjects performed 
presence and in the absence of symptoms. This goal 
may be achieved by the use of non-invasive methods 
and this approach might be useful also to characterize 
different inflammatory phenotypes of patients and to 
monitor their disease in order to better “personalize” 
the therapy. To date, only few studies have addressed 
the comparative use of non-invasive methods, 
including bronchial and nasal fractional exhaled 
nitric oxide (FE
NO
) and exhaled breath condensate 
(EBC), in patients with UAD (3).
FE
NO
 has been extensively studied as a potential 
non-invasive marker of asthma control and airway 
inflammation (1, 4) but, although the presence 
of correlation between FE
NO
 levels and clinical 
assessment (5) and between FE
NO 
and markers 
of oxidative stress, including 8-isoprostane and 
nitrotyrosine in EBC (6) have been demonstrated, 
the results supporting the routine use of these 
methodologies are still contradictory.
A large number of molecules measured in EBC, 
including leukotriene B
4
 (LTB
4
), Prostaglandin E
2
 
(PGE
2
) and 8-isoprostane, are considered a useful 
markers of airway inflammation and oxidative stress 
in the airways of asthmatic children (7-9). LTB
4
 is 
a pivotal biomolecule in the complex network of 
inflammatory mediators that characterizes allergic 
airway diseases; it is functionally involved in the 
neutrophilic inflammation of severe asthma and 
asthma exacerbations. Therefore, there are conflicting 
results on the role of LTB4 and 8-isoprostane since 
these markers seem to be relatively resistant to 
inhaled corticosteroids in allergic inflammation 
(9-11), although today 8-isoprostanes appear to 
be reliable biomarkers of oxidative stress during 
allergic airway inflammation (12). The relevant 
contribution of PGE
2
 in asthma pathogenesis has 
been demonstrated by its contribution to the increase 
of eosinophil survival (13). 
The aim of this study is to detect and to monitor 
the inflammation and the oxidative stress in the upper 
and lower airways of patients with atopic disease of 
UAD. This might allow to better understand the links 
between upper and lower airways and to have an 
insight in the assessment of the disease severity. In 
order to achieve this, we performed a cross-sectional 
study in atopic children with persistent AR (PER) 
and with different levels of asthma severity.  For this 
objective we measured the oral and the nasal FE
NO,
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pulmonary function tests according to the international 
guidelines (16). 
Assessment of atopic status
All subjects included in the study were assessed 
for atopic status which was established by clinical 
history and confirmed by SPT. Skin prick testing was 
performed as previously described (17). House dust mite 
(Dermatophagoides pteronyssinus and Dermotophagoides 
farinae) monosensitized patients were included in the 
study to select a population as homogeneous as possible 
and to avoid a bias caused by other allergen exposure. 
Serum samples were collected, and total serum IgE and 
specific IgE levels were determined by CAP System 
(Pharmacia-Upjohn, Uppsala, Sweden).
Spirometry
Baseline (forced expiratory volume in one second) 
FEV1 and forced vital capacity (FVC) were measured 
according to GINA guidelines (15). Baseline FEV1 was 
defined as the best of three reproducible curves. Patients 
were characterized by a reversible airway obstruction 
assessed by an increase of 15% of FEV
1
 after inhalation of 
200 µg of salbutamol.
Exhaled nitric oxide measurement
Oral and nasal FE
NO
 were determined by 
chemiluminescence (NIOX, Aerocrine, Sweden) following 
ATS/ERS recommendations (18). To evaluate the nasal 
FE
NO
, the nasal samples were obtained from 1 nostril. 
Patients were instructed to blow up the cheeks to elevate the 
mouth pressure to isolate the nasal cavity from the rest of the 
respiratory system (1). The reproducibility of oral and nasal 
FE
NO
 with these methods was previously assessed (1).
EBC collection
Oral EBC was collected using a commercially 
available condenser (EcoScreen; Jaeger, Wurzburg, 
Germany). Children were asked to breathe at a normal 
frequency and tidal volume, wearing a nose clip, for 15 
minutes. A median volume of 3 ml (2.6-3.5, percentiles) 
of oral EBC was collected.
Nasal EBC was collected according to Profita et al. (1). 
After applying a nasal mask to the EcoScreen condenser, 
children were asked to breathe through their noses, with their 
mouths closed. Before collection, the subjects were asked to 
rinse out their mouths. An aliquot of at least 1 ml of nasal 
condensate was collected and stored at -80°C in disposable 
polypropylene sterile tubes until analysed. A median volume 
of 2.3 ml (1.4-2.7, percentiles) of nasal EBC was collected. 
The reproducibility of oral and nasal EBC biomarkers with 
these methods was previously assessed (1). 
Alfa-amylase activity was determined to exclude 
salivary contamination as previously described (20). 
None of EBC samples contained detectable levels of 
amylase activity.
EBC measurements
Concentrations of 8-isoprostane were measured with a 
specific RIA developed as previously described (9). LTB
4
 
and PGE
2 
(Cayman Chemical, Milan, Italy) were assessed 
in EBC using commercially available specific EIA kits 
(10, 20). The detection limits for 8-isoprostane was 10 pg/
ml. The limits of detection were less than 6 pg/ml and 40 
pg/ml for LTB
4
 and PGE
2
 respectively. The reproducibility 
of EBC measurements was previously assessed (1). The 
intra-assay and inter-assay coefficients of variation for 
prostanoid RIAs were as follows: 8-isoprostane, < 2% and 
< 3%, respectively; PGE
2
 < 4% and < 5%, respectively. 
Intraclass correlation coefficient for 8-isoprostane and 
PGE
2
 were 0.95 and 0.90, respectively (21). The intra-
assay and inter-assay coefficients of variations for LTB
4
 
were < 10% and < 15%, respectively (22). The intraclass 
correlation coefficient for LTB
4
 was 0.72 (22).
Data analysis
Descriptive statistics were performed and quantitative 
data are expressed as median and percentiles (25 to 75 
%). Comparison of quantitative variables between the 
different groups was made by non-parametric Mann 
Whitney test. The correlations between variables were 
performed using Spearman test correlation. The P-value 
less than 0.05 were considered statistically significant for 
both non-parametric Mann Whitney test and Spearman 
test correlation. StatView statistical software (SAS 
Institute, Cary, NC, USA) was used.
RESULTS
Demographic, clinical and atopic characteristics of 
the subjects
Demographic, clinical and atopic characteristics 
of the subjects enrolled in the study are shown in 
Table I. 
Oral and nasal FE
NO
The levels of oral and nasal FE
NO
 were 
significantly higher in PER and in all asthmatic 
children than in HCs (Fig. 1A and B). No differences 
were observed among allergic children (Fig. 1A and 
B) (Table II). 
Measurement of 8-isoprostane in EBC
No significant differences were observed in 8-
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isoprostane levels in oral EBC among the study (Fig. 
1C) while 8-isoprostane concentrations in nasal EBC 
were higher in PER (P =0.007), IA (P =0.0012), mA 
(P = 0.008), and MA (P =0.006) than in HCs. No 
differences were observed among allergic patients 
(Fig. 1D) (Table II). 
LTB
4
 measurements in EBC
LTB
4
 concentrations in oral EBC were 
significantly higher in children with PER (P=0.04) 
Table I.Demographic, clinical and atopic characteristic of the subjects. 
 Characteristic HCs PER PER + Asthma P  value 
IA mA MA 
HCs
v
PAR
HCs
v
 IA 
HCs
v mA 
HCs
     v  
MA 
PAR
v
 IA 
PAR
v
 mA 
PAR
v
MA 
IA
v
mA 
IA
v
MA 
mA 
v
MA 
Subject number 13 14 25 28 13           
Male/Female 7/6 8/6 12/13 12/16 7/6           
Age (years) 10(9-12.3) 
12.5 
(10-15) 
9.0 
(8.0-12.3) 
11.0 
(9.0-11.0) 
10.0 
(8.0-13.0) 
NS NS NS NS NS NS NS NS NS NS 
FEV1 (% predicted) 
111.4 
(103-114) 
97.9 
(98.5-115) 
97.1 
(88.6-99.5) 
95.9 
(91-98.6) 
80.9 
(75.6-83.3) 
<0.004 <0.003 <0.003 <0.002 NS NS <0.002 NS <0.002 <0.0001 
Total IgE  (KU/ml) 89(78-102.5) 
318   
(172-460) 
388.5 
(278.5-697) 
516
(230-1067) 
685
(270-1612) 
<0.009 <0.0001 
<
0.0001 
<
0.0001 NS NS NS NS NS NS 
Blood Eosinophil 
number (mm3)
36.0 
(34-51.5) 
553
(263-600 ) 
414
(322-665) 
380
(204-497.5) 
528
(394-706.5) 
<
0.0001 
<
0.0001 
<
0.0001 
<
0.0001 NS NS NS NS NS <0.03 
Disease duration (years) none 4  (3-6) 5.8 (2.1-6) 5  (2.2-5) 5  (2.1-4.7)     NS NS NS NS NS NS 
Exacerbation number* none none 2 (0.5-2.8) 3.8  (0.9-6) 4  (1.5-7)        <0.04 <0.03 NS 
RAST to mite (kU/L) none 24.3 (11.1-37) 
34.0 
(13.9-47) 
38.9 
(19-40.9) 
40.2 
(19.9-50) 
    NS NS NS NS NS NS 
Results were expressed as median  (25-75 percentiles) 
Statistical analysis was performed by non-parametric Mann Whitney test 
*Number of exacerbation during 12 months 
Abbreviations: PER = perennial allergic rhinitis; FEV1 = forced expiratory volume in one second; HCs = healthy controls; IA = 
intermittent asthma;  mA = mild persistent asthma; MA = moderate persistent asthma 
Table I. Demograp i , clinical and atopic characteristic of the subjects.
Results were expressed as median  (25-75 percentiles)
Statistical analysis as performed by non-parametric Mann Whitney test
*Number of exacer tion during 12 months
Abbreviations: PER  perennial allergic rhinitis; FEV
1
 = forced xpiratory volume in one second; HCs = healthy 
controls; IA = intermittent asthma;  mA = mild persistent asthma; MA =  moderate persistent asthma
Table II. Levels of  FENO , 8-Isoprostane, LTB4 and PGE2 in Bronchial and Nasal EBC in allergic children. 
Subjects FENO (ppb) 8-Isoprostane (pg/ml) LTB4(pg/ml) PGE2 (pg/ml) 
Bronchial Nasal Bronchial Nasal Bronchial Nasal Bronchial Nasal 
HC 11.4
(6.1-15.1) 
180
(148-310) 
18.0
(16.0-30.0) 
14.0
(10.0-18.5) 
10.4
(0-54.8) 
18.5
(9.8-33.8) 
145.0
(106.7-159.9) 
176.1
(115.3-264.7) 
PER 25.0
(13.1-38.1) 
375.2
(330-460) 
18.0
(15.3-30.0) 
23.0
(19.0-32.0) 
31.4
(11.9-132.1) 
82.5
(24.0-186.0) 
290.5
(182-510) 
307.0
(170.6-672) 
PER+ IA  26.0
(14-54.6) 
410
(295.6-483) 
26.0
(18.8-31.8) 
26.0
(18.0-33.0) 
26.0
(6.5-38.0) 
27.4
(7.8-72.8) 
121.3
(59.3-161.5) 
181.5
(50.9-378.3) 
PER+ mA  21.8
(11.2-44.0) 
345.2
(235.3-440) 
23.5
(20.5-28.5) 
22.5
(15.5-30.0) 
44.0
(17.4-85.2) 
25.2
(20.5-58.6) 
73.8
(0-205.9) 
76.6
(21.8-203.2) 
PER+ MA  38.1
(20.2-56.3) 
410
(330.3-498) 
24.0
(19.8-34.0) 
21.0
(18.8-24.5) 
15.5
(0-38.0) 
3.2
(0-29.6) 
45.0
(4.9-139.9) 
27.4
(0-108.9) 
Results were expressed as median (25-75 percentiles) 
Table II. Levels of  FE
NO
 , 8-Isoprostane, LTB
4
 and PGE
2
 in Bronchial and Nasal EBC in allergic children.
Results were expressed as median (25-75 percentiles)
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and mA (P=0.012) than in HC subjects. LTB
4 
concentrations in oral EBC were also higher in 
children with PER (P=0.04) and mA (P=0.018) 
than in children with MA (Fig. 2A). The levels of 
LTB
4
 in nasal EBC were higher in children with 
PER (P=0.03) and mA (P=0.0064) than in HCs. 
Concentrations of nasal LTB
4
 were higher in PER 
(P=0.0064), IA (P=0.05) and mA children (P =0.01) 
Table III. Correlations between bronchial and nasal biomarkers in EBC. 
Markers PER PER+IA PER + mA PER +  MA 
FeNO (ppb) No correlations No correlations Rho=0.5 P= 0.01 No correlations
8-Isoprostane (pg/ml) No correlations No correlations Rho=0.5 P=0.01 No correlations
LTB4(pg/ml) No correlations Rho= 0.6 P= 0.007 
Rho=0.5 
P=0.03 No correlations
PGE2 (pg/ml) No correlations Rho= 0.8 P=0.0004
Rho=0.5 
P=0.01
Rho=0.8 
P=0.009
Statistical analysis was performed by Spearman test 
Table III. Correlations between bronchial and nasal biomarkers in EBC.
Statistical analysis was performed by Spearman test
Fig. 1. FE
NO 
and 8-isoprostane concentrations in 13 HC children, 14 children with PER and 62 children with asthma 
(25 children with IA, 28 children with mA and 13 children with MA, respectively). Panel A) concentrations of oral FE
NO
. 
Panel B) concentrations of nasal FE
NO
. Panel C) concentrations of 8-isoprostane in oral EBC. Panel D) concentrations 
of 8-isoprostane in nasal EBC. Data are shown as individual data. Statistical analysis was performed by Kruskall-Wallis 
test and Dunn procedure. *p <0.05. Horizontal bars represent median values.
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than in MA children (Fig. 2B) (Table II). 
PGE
2
 measurements in EBC
The levels of PGE
2
 in EBC were significantly 
higher in PER than in HCs (P =0.02), while lower 
levels were observed in MA (P=0.0026) and mA (P 
= 0.014) than in PER. The concentrations of PGE
2
 in 
nasal EBC were higher in PER than in HC subjects (P 
=0.04). PGE
2
 concentrations were higher in children 
with PER than in children with mA (P=0.007) and 
MA (P=0.004). Children with IA had higher PGE
2
 
concentrations than children with MA (P =0.02) 
(Fig. 2D) (Table II).
 
Correlations between bronchial and nasal FE
NO
, 8-
isoprostane, LTB
4
, and PGE
2
In children with IA, positive correlations 
between oral and nasal EBC concentrations of LTB
4
 
(P=0.007, r=0.6) and between oral and nasal EBC 
concentrations of PGE
2
 (P =0.0004, r =0.8) were 
observed (Table III). 
In children with mA, there was a correlation 
between bronchial and nasal FE
NO
 concentrations 
(P=0.011, r =0.5), and between oral and nasal EBC 
concentrations of 8-isoprostane (P =0.01, r =0.5), 
LTB
4
 (P =0.03, r = 0.5), and PGE
2
 (P=0.01, r =0.05) 
(Table III).
In patients with MA, a correlation between oral 
and nasal EBC PGE
2
 (P 0.009, r =0.8) was observed 
(Table III).
No correlations between markers of bronchial 
and nasal oxidative stress and inflammation were 
observed in children with PER and in HCs (Table 
III). 
DISCUSSION
The present study investigates the levels of 
FE
NO
, LTB
4
, PGE
2
 and 8-isoprostane in both upper 
and lower airway compartments of children with 
PER and with PER and different levels of asthma 
demonstrating that the presence of these markers is 
relevant in both districts, despite the big variability 
and the marginal differences in the groups. The 
Fig. 2. EBC LTB
4
 and PGE
2
values in 13 HC children, 14 children with PER and 62 children with concomitant PER and 
asthma (25 children with IA, 28 children with mA and 13 children with MA, respectively). Panel A) concentrations of 
LTB
4
 in oral EBC. Panel B) concentrations of LTB
4 
in nasal EBC. Panel C) concentrations of PGE
2
 in oral EBC. Panel D) 
concentrations of PGE
2 
in nasal EBC. Data are shown as individual data. Statistical analysis was performed by Kruskall-
Wallis test and Dunn procedure. * P < 0.05. Horizontal bars represent median values.
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correlations between these markers and their 
persistence, despite children with PER and asthma 
being treated for asthma,  might be able to mirror a 
relationship between biomarkers in the two airway 
compartments that might be useful to monitor and to 
phenotype UAD. 
The high levels of FE
NO
 in both nasal and oral 
compartments of MA suggest that the oxidative stress 
associated with FE
NO
 might not be well controlled by 
recommended doses of inhaled corticosteroids (ICS). 
The presence of a positive correlation between the 
levels of oral and nasal FE
NO
 in children with mA is 
a further confirmation of the UAD concept, also in 
these patients with low levels of asthma severity.  In 
addition, the fact that this correlation is not present 
in children with PER, IA and MA is consistent with 
a lower inflammatory burden in PER and IA. These 
results could be explained by the effects of ICS 
promoting a modification of FE
NO
 concentrations in 
both bronchial and nasal compartments of children 
with MA. On the other hand the issue that the 
assessment of relationship between bronchial and 
nasal levels of FE
NO
 is able to provide information 
about the effect of the treatment on inflammation in 
asthmatic children is consistent with the observation 
that in children with mA, treated with lower levels of 
ICS than MA patients, the correlations between the 
oral and nasal levels of FE
NO
 are persistent despite 
symptomatic and functional control of the disease.  
The positive correlation between the levels 
of nasal and oral EBC 8-isoprostane in mA 
children with PER suggest that the concomitant 
nasobronchial evaluation of 8-isoprostane, together 
with the detection of the nasobronchial FE
NO
, may 
be useful to biochemically phenotype this group of 
asthmatic children. Finally, there was no correlation 
between nasal and oral EBC 8-isoprostane in MA 
children with PER who received higher doses of 
ICS, suggesting that ICS might affect the interaction 
of nasal and bronchial inflammation.
     We observed higher levels of nasal and oral 
EBC LTB
4
 in mA children than in HCs, suggesting 
that the nasal-oral LTB
4
-mediated inflammation 
persists despite treatment with ICS (9). Finally, we 
found a positive correlation between nasal and oral 
EBC LTB
4
 concentrations in children with both IA 
and mA, suggesting that only treatment of both areas, 
the nose and bronchi, may lead, in these specific 
inflammatory phenotypes, to a complete control of 
upper and lower airway inflammation. 
We showed higher levels of oral EBC and 
nasal PGE
2
 concentrations in children with PER, 
indicating lower airway inflammation also in the 
absence of asthma symptoms. The presence of a 
positive correlation between nasal and oral EBC 
concentrations of PGE
2
 in children with IA, mA and 
MA, is in agreement with the concept of UAD and 
with its relevant contribution in the pathogenesis of 
asthma. In addition, the findings that children with 
stable MA had lower LTB
4
 and PGE
2
 concentrations 
in oral and nasal EBC suggest that elevated doses 
of ICS might control both bronchial and nasal 
inflammation, likely through the involvement of 
humoral mechanisms involved in the interaction of 
the upper and lower airways in UAD (23). These 
results support the concept that the treatment 
of asthma may have a beneficial effect on the 
concomitant rhinitis (24-25).
The strength of this paper is to identify 
correlations between nasal and oral inflammation 
and oxidative stress in children with concomitant 
PER and different degrees of asthma defining 
“one-way/one-disease”. The persistence of some 
correlations might identify inflammatory phenotypes 
of children with allergic airway disease and might 
help to plan an individualized therapy for UAD 
management. Nevertheless, the strong message of 
this paper needs to be further investigated opening 
new perspectives for larger and longitudinal studies 
aimed at assessing the concomitant evaluation of 
naso-bronchial markers of oxidative stress and 
inflammation to better manage children with UAD. 
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